Opendata, web and dolomites

SPELITEC SIGNED

Sequence sPecific ELImination of shiga-Toxin E. Coli

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SPELITEC project word cloud

Explore the words cloud of the SPELITEC project. It provides you a very rough idea of what is the project "SPELITEC" about.

treatment    paediatric    microbiota    liquid    disrupting    spelitec    batch    elimination    compound    antibiotic    young    mutation    mix    mechanism    nature    haemolytic    bacterial    disease    coli    humans    background    progression    gel    companies    initiate    orally    eligo    capsid    eliminates    selectively    conducting    validated    individualised    antibodies    dialysis    medical    receptors    receive    launch       patient    first    clinical    coupled    toxins    company    validation    finalise    treatments    toxin    animals    market    indication    model    empts    eb003    release    alternative    stec    clinically    team    plans    transfusions    business    rehydration    orphan    drug    inducing    designed    variants    action    fatal    healthy    shiga    solid    strains    exert    patients    administered    stecs    uremic    safe    children    validate    producing    primary    authorization    multinational    complete    spectrum    toxicity    preclinical    infections    license    resistance    populations    complications    therapeutic    unmet    pharmacological    multivalent    tests    bacteria    consisting    acquisition    safety    pharma    symptomatic    hospitalized   

Project "SPELITEC" data sheet

The following table provides information about the project.

Coordinator
ELIGO BIOSCIENCE 

Organization address
address: 29 RUE FAUBOURG SAINT JACQUES PEPIN
city: PARIS
postcode: 75014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙948˙250 €
 EC max contribution 2˙763˙775 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELIGO BIOSCIENCE FR (PARIS) coordinator 2˙763˙775.00

Map

 Project objective

SPELITEC is the first treatment for Shiga toxin-producing E. coli (STEC) infections, which affects primary young children and can be fatal in 1-5% of the cases. Currently there is no validated safe treatment: hospitalized patients receive only symptomatic treatments consisting of rehydration coupled with transfusions and dialysis for haemolytic uremic complications. The SPELITEC program is designed to finalise preclinical and initiate clinical studies for elimination of STEC bacteria (Shiga-toxin producing E. coli) in paediatric populations with a dedicated product: EB003. EB003 selectively eliminates STEC bacteria early in the disease progression; it is not expected to exert any toxicity in humans or animals; it is a multivalent mix of different capsid variants allows to target the whole spectrum of clinically relevant strains and pre-empts the acquisition of resistance through mutation of bacterial receptors; it is administered orally by a liquid/gel which is patient-friendly and adapted to young children and it represents a cost-effective alternative to antibodies against Shiga toxins. Our technology is the only one allowing the specific elimination of STECs without toxin release and without disrupting microbiota and inducing antibiotic resistance. Eligo will complete early drug development, which should ensure market authorization given the orphan and unmet medical need nature of the indication, and plans to out-license the compound to an established pharma company that will launch the product on the market. The management team of Eligo has solid business and technical management experience in multinational companies and a very strong drug development background. During the Phase 2 project we will validate this new individualised therapeutic approach and mechanism of action by conducting the validation of the pharmacological model, the production of a clinical batch and the safety tests in healthy animals.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPELITEC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPELITEC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More